While anti-vascular endothelial growth factor (anti-VEGF) therapy has achieved substantial success in managing wet AMD, effective treatment is still needed for the late-stage form, which is characterized by submacular neovascularization or disciform scar. Here, VEGFA is linked to wet macular degeneration.